Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain

Gossamer Bio (NASDAQ:GOSS) reported top-line results from PROSERA, its global phase III registrational study evaluating ...
GlobalData on MSN

Gossamer Bio reports topline Phase III PROSERA outcomes for PAH

Of the 390 patients enrolled, 197 received seralutinib and 193 received placebo.

Gossamer Bio Misses Primary Endpoint Threshold on Pulmonary Arterial Hypertension Drug Study

Gossamer Bio's phase three study of its seralutinib drug for Pulmonary Arterial Hypertension did not meet the statistical threshold for its primary endpoint. Shares fell 82% to 38 cents in premarket ...
STAT

Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval

Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.

Gossamer Bio shares plummet as lung disease drug fails late-stage trial

By Sahil Pandey and Siddhi Mahatole Feb 23 (Reuters) - Gossamer Bio's experimental treatment failed to significantly improve ...
Tampa Free Press on MSN

Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study

San Diego-based Gossamer Bio released long-awaited Phase 3 data today for its drug seralutinib, revealing a complex set of results that both challenged and encouraged researchers. The PROSERA study, ...

Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation

Study represents a significant advancement in Grove’s Bionic Biologics™ platform – CHICAGO--(BUSINESS WIRE)--February 24, 2026-- Grove Biopharma, ...
STAT

What to expect from Gossamer Bio’s late-stage lung disease study

Gossamer Bio will be reporting the outcome of a late-stage study in pulmonary arterial hypertension. Here's what to know.
AgWeb

Study finds Pivot Bio PROVEN® 40 Increases Grower Revenue

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...